<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119934</url>
  </required_header>
  <id_info>
    <org_study_id>19-231</org_study_id>
    <nct_id>NCT04119934</nct_id>
  </id_info>
  <brief_title>Personalized Smoking Cessation Infographic in COPD</brief_title>
  <official_title>Personalized Biomedical Risk Assessment for Smoking Cessation in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effect of a personalized smoking cessation infographic on physician
      smoking cessation counseling rates and smoking cessation pharmacotherapy prescription rates.
      The study assesses the difference in physician behaviour using a one-year pre (control arm)
      vs. one-year post (intervention arm) trial period. General practitioners, nurse practitioners
      and respirologists who refer eligible patients (COPD, active smoking) for spirometry at the
      St. Michael's Hospital, Toronto Western Hospital, Women's College Hospital and Sunnybrook
      Hospital Pulmonary Function Labs will receive the infographic. This is a quality improvement
      initiative.

      The smoking cessation infographic uses individualized patient data (height, weight, sex,
      baseline FEV1, etc.) to produce a personalized lung function decline prediction over the next
      15 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) affects 11.8% of adult Ontarians, remains the
      leading cause of hospitalization in Canada, and cost the Canadian economy $770 million in
      2010. Smoking cessation reduces mortality and improves quality of life in COPD, and also
      reduces the risk of developing stroke, coronary heart disease, and several types of cancer.
      Despite this evidence, 45% of patients with COPD continue to smoke.

      Previous trials have demonstrated that even brief smoking cessation advice offered by a
      physician can increase quit rates, with intensive interventions proving additionally
      effective. Despite this, only 37% of US and 54% of Canadian smokers who had a visit with a
      physician during the prior year had been advised to quit smoking. Barriers and enablers
      underlying this care gap are multi-fold. At the patient level, barriers to quitting include
      accessibility of appropriate therapy, low expectations of quit success (self-efficacy) and
      low expectations of risk mitigation by quitting (outcome expectancy). Enablers include easily
      available therapy, knowledge of ongoing smoking effects, and motivation to quit for personal
      gain. For clinicians, barriers to providing smoking cessation advice include perceived lack
      of cessation counseling skills (self-efficacy), lack of time, memory (forgetting to do it),
      and concerns about harming the doctor-patient relationship. Enablers include reminders to
      provide cessation advice and improved outcome expectancy (a belief that their patients have a
      reasonable chance of quitting).

      Among different lung function metrics, forced expiratory volume in one second (FEV1) is the
      best validated metric for quantifying the degree of lung function impairment and is used to
      define disease severity. Our group previously developed and validated a prediction tool that
      uses individual patient characteristics to predict a personalized rate of future FEV1
      decline. Considering the barriers and enablers to effective smoking cessation interventions
      noted above, our team then designed a smoking cessation intervention centered on this lung
      function decline calculator. Given that smoking is a modifiable variable that affects the
      rate of lung function decline, we translated the original calculator into a clinical
      infographic which quantitatively demonstrates the consequences of quitting versus continuing
      smoking on lung function and its correlated patient-relevant outcomes, for each individual
      patient (i.e. a personalized biomedical risk assessment). This approach was informed by
      previous studies demonstrating the promise of biomedical risk assessment (the process of
      giving smokers feedback on the physical effects of smoking using physiological measurements)
      and tailored educational materials for smoking cessation. Such tools can enhance smoking
      cessation consultations, particularly when educational material is in a visual format. We
      first designed a prototype tool according to best infographic design and content evidence and
      then conducted a series of iterative 2-hour moderated focus groups with 4-5 COPD patient
      participants per group and semi-structured 1-on-1 interviews with respirologists, until
      saturation of themes [4 focus groups (20 participants), 4 interviews]. In a rapid cycle
      design process, we made changes to tool content and format after each focus group and
      interview, based on qualitative analysis of feedback.

      This infographic is designed for clinicians to use as a facilitator for smoking cessation
      intervention delivery with their patients. It demonstrates expected FEV1 decline with and
      without smoking cessation, and corresponding patient-relevant morbidities (page 1), and
      provides clinicians with guidance for smoking cessation pharmacotherapy prescriptions (page
      2). With this project, we seek to evaluate this tool in real-world practice to determine
      implementation feasibility and preliminary impact. The tool will not only act as a prompt for
      clinicians to provide smoking cessation counseling, but also serves to improve their
      self-efficacy and to enhance outcome expectancy with respect to smoking cessation advice. In
      turn, it provides patients with a personalized analysis of the future impact of their smoking
      and the benefit of a quit, with a goal of enhancing motivation to quit.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who receive a smoking cessation counselling intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Using prospective chart review, we assess the proportion of patients who receive a smoking cessation intervention in conjunction with tool use (smoking cessation infographic). Chart review will look for evidence of tool use with the patient at the visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of patients who receive smoking cessation pharmacotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Using prospective chart review, we assess the proportion of patients who receive smoking cessation pharmacotherapy in conjunction with tool use (smoking cessation infographic). Chart review will look for evidence of tool use with the patient at the visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in rates of spirometry referrals</measure>
    <time_frame>12 months</time_frame>
    <description>A review of the pulmonary function lab visits in the one-year and one-year post periods will assess whether there was an increase in the number of spirometry referrals from the enrolled physicians</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in respiratory medication prescriptions</measure>
    <time_frame>12 months</time_frame>
    <description>Chart review will qualitatively record changes in respiratory medication prescriptions in visits where the tool was used. Data will be analyzed in aggregate to look for trends</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking cessation billing code changes</measure>
    <time_frame>12 months</time_frame>
    <description>Chart review will assess any changes in billing codes used for smoking cessation in visits where the tool was used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative user feedback for the tool</measure>
    <time_frame>12 months</time_frame>
    <description>Exclusively throughout the intervention, electronic questionnaires and telephone interviews will be solicited to assess user feedback on: barriers/enablers to use, feasibility, effect on workflow, perceived usability, quality and impact on smoking cessation counseling delivery and effectiveness.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Control - None</arm_group_label>
    <description>A retrospective chart review will assess physician behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention - Smoking cessation infographic</arm_group_label>
    <description>Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians (for eligible patients). Chart review will be conducted for the patient's physician within a three-month window of receiving the infographic to assess outcomes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation Intervention Tool</intervention_name>
    <description>A personalized smoking cessation infographic is provided to the physician alongside the patient's regular spirometry report.</description>
    <arm_group_label>Intervention - Smoking cessation infographic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of clinicians in primary care and hospital settings in
        Toronto, Canada.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligible clinicians will include respirologists, general practitioners and nurse
        practitioners who refer patients for spirometry testing at the St. Michael's Hospital
        Toronto Western Hospital, Women's College Hospital and Sunnybrook Hospital Pulmonary
        Function Lab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samir Gupta, MD, MSc</last_name>
    <phone>(416) 864-6060</phone>
    <phone_ext>2252</phone_ext>
    <email>samir.gupta@unityhealth.to</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Samir Gupta, MD, MSc</last_name>
      <phone>(416) 864-6060</phone>
      <phone_ext>2252</phone_ext>
      <email>samir.gupta@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Samir Gupta, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&amp;Id=30140</url>
    <description>Statistics Canada. Canadian Tobacco Use Monitoring Survey (CTUMS): Detailed Information from February to June 2006</description>
  </link>
  <reference>
    <citation>Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233-9.</citation>
    <PMID>15710956</PMID>
  </reference>
  <reference>
    <citation>Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003 Mar;97 Suppl C:S23-31.</citation>
    <PMID>12647940</PMID>
  </reference>
  <reference>
    <citation>Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? 1998. Milbank Q. 2005;83(4):843-95.</citation>
    <PMID>16279970</PMID>
  </reference>
  <reference>
    <citation>Zafari Z, Sin DD, Postma DS, LÃ¶fdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SFP, Tashkin D, Wise RA, Connett JE, McManus B, Ng R, Hollander Z, Sadatsafavi M. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ. 2016 Oct 4;188(14):1004-1011. doi: 10.1503/cmaj.151483. Epub 2016 Aug 2.</citation>
    <PMID>27486205</PMID>
  </reference>
  <reference>
    <citation>Voncken-Brewster V, Tange H, de Vries H, Nagykaldi Z, Winkens B, van der Weijden T. A randomized controlled trial evaluating the effectiveness of a web-based, computer-tailored self-management intervention for people with or at risk for COPD. Int J Chron Obstruct Pulmon Dis. 2015 Jun 8;10:1061-73. doi: 10.2147/COPD.S81295. eCollection 2015.</citation>
    <PMID>26089656</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

